Cargando…

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer

The majority of high-grade serous ovarian cancers (HGSCs) are deficient in homologous recombination (HR) DNA repair, most commonly due to mutations or hypermethylation of the BRCA1/2 genes. We aimed to discover how BRCA1/2 mutations shape the cellular phenotypes and spatial interactions of the tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Launonen, I.-M., Lyytikäinen, N., Casado, J., Anttila, E. A., Szabó, A., Haltia, U.-M., Jacobson, C. A., Lin, J. R., Maliga, Z., Howitt, B. E., Strickland, K. C., Santagata, S., Elias, K., D’Andrea, A. D., Konstantinopoulos, P. A., Sorger, P. K., Färkkilä, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837628/ https://www.ncbi.nlm.nih.gov/pubmed/35149709 http://dx.doi.org/10.1038/s41467-022-28389-3

Ejemplares similares

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
por: Strickland, Kyle C., et al.
Publicado: (2016)

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
por: Färkkilä, Anniina, et al.
Publicado: (2020)

Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
por: Färkkilä, Anniina, et al.
Publicado: (2020)

UnMICST: Deep learning with real augmentation for robust segmentation of highly multiplexed images of human tissues
por: Yapp, Clarence, et al.
Publicado: (2022)

Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer
por: Kiely, B. E., et al.
Publicado: (2011)

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2
por: Clarfield, Lauren, et al.
Publicado: (2022)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations
por: Shukla, Sachet A., et al.
Publicado: (2016)

The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution
por: Nirmal, Ajit J., et al.
Publicado: (2022)

Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer
por: Perez-Villatoro, Fernando, et al.
Publicado: (2022)

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
por: Dougherty, Brian A., et al.
Publicado: (2017)

SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance
por: Sheets, J N, et al.
Publicado: (2016)

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
por: Ding, Liya, et al.
Publicado: (2018)

Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?
por: McCuaig, Jeanna M., et al.
Publicado: (2022)

Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers
por: Mouw, Kent W., et al.
Publicado: (2015)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer
por: Rashid, Rumana, et al.
Publicado: (2019)

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2018)

BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography
por: Sobecki, Janelle N., et al.
Publicado: (2020)

Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation
por: Chong, Gun Oh, et al.
Publicado: (2020)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
por: Pikkusaari, Sanna, et al.
Publicado: (2023)

Cell Spotter (CSPOT): A machine-learning approach to automated cell spotting and quantification of highly multiplexed tissue images
por: Nirmal, Ajit J., et al.
Publicado: (2023)

Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4
por: Guillemette, Shawna, et al.
Publicado: (2015)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors
por: Stroot, Iris A.S., et al.
Publicado: (2023)

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
por: Osorio, A, et al.
Publicado: (2009)

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
por: Conroy, Michael, et al.
Publicado: (2017)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment
por: Gonzalez, Veronica D., et al.
Publicado: (2021)

Mutation Analysis of BRCA1 and BRCA2 in Italian Hereditary and Sporadic Forms of Breast and Ovarian Cancers: Tumor Genotype-Phenotype Correlation in Breast Cancer BRCA-Mutation Carriers
por: Cipollini, G., et al.
Publicado: (1999)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1.
por: Lancaster, J. M., et al.
Publicado: (1998)

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
por: Whittemore, A S, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_t01dg9jjia65p4ak2l8at1dg8r